Introduction 86 87
Candida albicans is an ascomycete fungus that is an important commensal and 88 opportunistic pathogen in humans. Systemic infections resulting primarily from this yeast and 89 the filamentous fungus, Aspergillus fumigatus, are associated with mortality rates of 50% or 90 greater despite current therapies 1-3 . Therapeutic options are limited to treatment with mainly 91 three antifungal classes, namely polyenes, azoles and echinocandins 4 . These compounds target 92 the specific fungal biological process of ergosterol metabolism (azoles and polyenes) and cell 93 wall β -1,3-glucan synthesis (echinocandins). However, these drugs have serious side effects such 94 as nephrotoxicity and/or create complications such as resistance and interactions with other 95 commonly prescribed drugs. There are currently a limited number of novel antifungal molecules 96 on the drug discovery pipelines and most of them target the same cellular processes as azoles and 97
echinocandins [5] [6] [7] . Thus, these molecules will most likely face the same limitations in term of 98 resistance and toxicity. These considerations highlight the urgent need to identify novel targets 99 and strategies for antifungal therapies 100 101
The pathogenicity of C. albicans is mediated by different factors such as invasive filamentation, 102 biofilm formation and the ability to escape the immune system 4 . A relatively new but poorly 103 exploited paradigm in the antimicrobial therapy field is to target virulence traits for drug 104 development 8, 9 . In contrast to target-focused approaches, phenotypic screens enable 105 identification of bioactive molecules that induce a desirable biological readout without making a 106
priori assumption about the cellular target. Additionally, compounds identified by phenotypic 107 screens are by definition cell permeable and engage their target with sufficient affinity. Taking 108 into consideration the commensal lifestyle of C. albicans, suppressing its growth in different 109 niches inside the host will perturb the microbial flora equilibrium and lead to other opportunistic 110 infections 10 . Specific inhibition of fungal virulence determinants without affecting commensal 111 growth represents thus an attractive approach. 112 113 C. albicans is a polymorphic fungus that are able to reversibly shift to different morphologies 114 including yeast, pseudohyphae and true hyphae forms. Hyphae are long tubular cells that are 115 associated with the invasion of organs and tissues of the human host during Candidemia 116 episodes. 117
In addition to ensuring a physical force required to penetrate host cells, the hyphae state is 118 characterized by an enhanced adhesiveness and allow to the fungal cells to escape the from 119 phagocytes and to conquer niches where nutrient conditions are not limiting 11 . Furthermore, 120 even if hyphae are not essential for the formation of C. albicans biofilms, they are determinant 121 for the compression strength and the resistance to mechanical dislocation of this highly resistant 122 growth lifestyle 12 . Thus, antivirulence therapy based on molecules that inhibit hyphae formation 123 could have substantial benefits on managing fungal infections. Moreover, antivirulence agents 124 might provide an alternative strategy to circumvent antifungal resistance by disarming fungal 125 resistant pathogens from their virulence factors 13 . 126 127
Proof of principle for this concept has been demonstrated in different investigations [14] [15] [16] [17] [18] [19] . Fazly 128 et al. characterized a small molecule called filastatin that inhibits C. albicans filamentation, 129 adhesion and virulence 15 , yet, the molecular mechanism by which this molecule acts remain 130 elusive. Recently, screening of small molecules that are being clinically tested for different 131 pathologies identified two antifilamentation compounds that also perturbed endocytosis 16 . 132 However, these compounds were also found to inhibit the commensal yeast growth at the 133 effective antifilamentation concentrations. 134 135
In this study, we screened a chemical library of 678 small molecules that were preselected for 136 bioactivity in the budding yeast S. cerevisiae and have well-balanced hydrophilic-lipophilic 137
properties allowing the crossing of both the hydrophilic fungal cell wall and the lipophilic 138 membrane. We found that N1-(3,5-dichlorophenyl)-5-chloro-2-hydroxybenzamide (TCSA: Chloro-Salicyanilide, for simplified nomenclature), a halogenated salicylanilide, was a potent 140 antifilamentation molecule and inhibited also biofilm formation of both C. albicans and the 141 multi-resistant yeast C. auris. The TCSA analog, Niclosamide, that is an FDA-approved 142 anthelmintic agent, exhibited a similar anti-filamentation and anti-biofilm activities and 143 conferred a significant protective activity to intestinal epithelial cells against fungal invasion. 144
Both genome-wide transcriptional profiling and chemical-genetic approach were used to gain 145 insight into the mechanism of action associated with the antivirulence activity of the halogenated 146 salicylanilides (HSA). We found that HSA-mediated antivirulence activity is likely related to the 147 perturbation of the fungal mitochondrial protein import machinery. 148 149
Results

150
Phenotypic screening of yeast-bioactive small molecules for inhibition of hyphal growth 151
To identify small molecules with antivirulence properties the yeast bioactive small molecule 152 library 20 was screened for compounds that inhibit hyphal formation (Fig. 1A) . Compounds of 153 this chemical library were preselected for bioactivity in S. cerevisiae and have well-balanced 154 hydrophilic-lipophilic properties allowing the crossing of both the hydrophilic fungal cell wall 155 and the lipophilic membrane. C. albicans cells were grown in 96-well under hyphae-promoting 156 conditions (SC-10% fetal bovine serum (FBS)) for 3h at 37 °C in the presence of the bioactive 157 compounds. The ability of each compounds to inhibit C. albicans SC5314 strain morphogenesis 158 was assessed by imaging each well using the high-content microscope Cytation 5. This primary 159 screen identified 93 molecules with anti-filamentation activity at 100µM (70-80% of C. albicans 160 cells with no germ tubes). A total of 50 promiscuous molecules with chemical structures similar 161 to pan assay interference compounds (PAINS) associated with antifungal activity 21 were 162 removed from the hit list of the primary screen. Inhibition of filamentation could be associated 163 with the fact that small molecules are very toxic which might systematically alter all 164 developmental process of a fungal cell such as morphogenesis. To rule out cytotoxic molecules 165 that impaired growth per se, the 43 retained hits were assayed for their ability to inhibit growth 166 of yeast cells growing at 30°C. Through this process, a subset of five molecules were selected 167 which were then assayed for their potency using a quantitative dose-response filamentation 168 inhibition assay. Among the five hits, we found two molecules that had a significant effect on 169 filamentous growth at pharmacological concentrations of 1-10µM (data not shown). The effect 170 of this compounds on C. albicans filamentation were confirmed using a new batch of powders 171 from different suppliers ( Fig. 1B-C) . 172 173
Compound #1 (N1-(3,5-dichlorophenyl)-5-chloro-2-hydroxybenzamide or TCSA) is a 174 halogenated form of salicylanilide scaffold. Salicylanilides are widely used as antiparasitic 175 veterinary drugs against helminths and ectoparasites 22 . The salicylanilide Niclosamide (5-176 chloro-salicyl-(2-chloro-4-nitro) anilide) was approved by the FDA to treat tape worm infection 177 release assay in cells treated or not with different concentrations of the two HSA. Our data 224 showed clearly that both antifilamentation compounds significantly reduced, but not completely 225 abolished, the damage to HT-29 enterocytes (Fig. 4E) . The protective effect was perceived at 226 40µM of either Niclosamide or TCSA (~ 20% reduction of enterocyte invasion). At 227 concentration ≥100µM , Niclosamide and TCSA attenuated HT-29 cell damage by 63% and 49%,  228 respectively. 229 230
Niclosamide induces retrograde response in C. albicans 231
To gain insight into the mechanism of action associated with the antifilamentation effect of HSA, 232 transcriptional profiling was undertaken on cells grown under hyphae-stimulating conditions in 233 the presence of 50µM of Niclosamide. Gene ontology analysis showed that transcripts related to 234 drug transport and, carbohydrate, trehalose and glyoxylate metabolisms were induced while 235 genes of cell wall, filamentation and lipid metabolism including ergosterol (ERG6, ERG25, 236 CYB5, NDT80), sphingolipids (LCB2, FEN1, LAC1) and phosphoglycerides (AYR1, CHO2, 237 PEL1, EPT1, YEL1, DGK1) were downregulated ( Table 1 ). We also found that genes encoding 238 different proteins that control the activity of different protein kinases such as those modulating 239 cell cycle progression (CLN3, CLG1, SOL1, CIP1) were repressed in response to Niclosamide. 240 Gene expression alteration of eight genes including four upregulated (ICL1, MLS1, MDR1, 241 GDH2) and four downregulated (ZRT2, ERG25, LAC1, CDC47) transcripts was confirmed using 242
qPCR (Table S1 ). 243 244
Of note, transcripts of the isocitrate lyase, ICL1, and the malate synthase, MLS1, both key 245 enzymes of glyoxylate cycle were highly induced (46-and 13-fold induction for ICL1 and MLS1, 246 respectively) ( Fig. 5A and Table S2 ). The glyoxylate cycle is an anaplerotic pathway of the 247 tricarboxylic acid (TCA) cycle that allows assimilation of carbon from C 2 compounds by 248 bypassing the CO 2 -generating steps of the TCA cycle. Both Icl1 and Mls1 enzymes are  249 perxisomal, unique to the glyoxylate route and are not shared with the tricarboxylic acid (TCA)  250 cycle 35, 36 . Activation of those genes in response to Niclosamide suggests a metabolic 251 reconfiguration where acetyl-CoA is supplied by the glyoxylate cycle instead of the TCA cycle, 252 which might be compromised ( Fig. 5A) . This transcriptional signature is characteristic of the 253 retrograde (RTG) response, which is a mitochondria-to-nucleus signaling that cells activates as a 254 cytoprotective mechanism to compensate for mitochondrial dysfunctions 37 . Another supportive 255 evidence of the TCA cycle failure, is reflected by the activation of genes that mediate other 256 anaplerotic reactions to supply the TCA cycle with intermediates from alternative pathways. This 257 includes the cytoplasmic pyruvate carboxylase enzyme, Pyc2, that converts the pyruvate to 258 oxaloacetate. Transcript level of the glutamate dehydrogenase, Gdh2, that degrades glutamate to 259 ammonia and alpha-ketoglutarate, were also induced (2.67-fold change), however, the levels of 260 induction were not consistent enough (p = 0.21) for it to pass the threshold of statistical 261 significance. 262 Activated transcripts were also enriched in genes encoding many proteins with oxidoreductase 263 activity which might reflect a compensatory response to reoxidize the NADH as a consequence 264 of TCA and mitochondrial electron transport failures. Reactivation of glycolytic regulatory genes 265
PFK26 and PFK27 suggests also an adaptation to the drop of the intracellular level of ATP as a 266
result of mitochondrial dysfunction. The strong upregulation of the alternative oxidase transcript, 267
Aox2 (31.5-fold induction), emphasizes that C. albicans cells might use this alternative electron 268 transport systems to bypass the lack of mitochondrial electron transport. Taken together, the  269  Niclosamide-transcriptional signature is reminiscent of cells experiencing an RTG response as a  270 consequence of impaired mitochondrial activity. 271 Antifilamentation activity of Niclosamide and TCSA against C. albicans azole-resistant 272 strains 273
In response to Niclosamide, C. albicans cells induced the expression of transporters such as Cdr1 274
and Mdr1 that are a key determinant of antifungal clinical resistance in this human pathogen 38-40 . 275 This reflect that C. albicans is trying to expel Niclosamide through efflux process. This prompt 276 us to check whether antifungal resistance mediated by efflux process might bypass the 277 antifilamentation effect of HSA. Both Niclosamide and TCSA were tested on clinical strains for 278 which azole resistance is mediated by MDR1 (strain 6692) and CDR1 (strain 5674) 279
overexpression. As shown in Fig. 5B -C, the antifilamentation effect of the two salicylanilides on 280 these two resistant isolates was similar to that noticed for the SC5314 sensitive clinical strain. 281
This emphasizes that Niclosamide and TCSA could be used to compromise C. albicans 282 filamentation of both azole-sensitive and resistant strains. 283
Niclosamide and TCSA alter the mitochondrial membrane potential 284
In the budding yeast, RTG response is triggered by the loss of mitochondrial membrane potential 285
(ΔΨm) as a consequence of mitochondria dysfunction 41 . Thus, Niclosamide or TCSA might 286
induce RTG in C. albicans by promoting the perturbation of the ΔΨm. Change in ΔΨm was 287 quantitatively assessed using JC-1, a green fluorescent potentiometric dye that shifts to red 288 fluorescence as a consequence of ΔΨm. C. albicans cells treated with either Niclosamide or 289
TCSA exhibited a collapse of the ΔΨm which was obvious at the concentration of 5µM ( Fig.  290  5D) . The effect of both HSA on the failure of ΔΨm was also confirmed using the MitoTracker 291 dye that stains and accumulate in mitochondria dependently on ΔΨm 42 (Fig. 5E) . These data 292
suggest that both HSA induce RTG response in C. albicans as consequence of the alteration of 293
ΔΨm.
295
Mutants of the mitochondrial protein import machinery are required for Niclosamide 296 tolerance and filamentation 297
Chemical-genetic assays such as the haploinsufficient profiling (HIP) is a powerful tool that has 298 been widely used to uncover the mechanism of action (MoA) of many bioactive compounds 43-46 . 299 The principle of the HIP assay is based on the fact that decreased dosage of a drug target gene in 300 a heterozygous mutant can result in increased drug sensitivity. To investigate the MoA of the 301 HSA associated with their antifilamentation activity, we mined the data of HIP experiments 302 performed in the yeast model S. cerevisiae in two resource studies 47, 48 . Hoepfner et al. 47 has 303 performed HIP assay for Niclosamide while other analogs similar to HSA were investigated 304 using the same approach by Corey Nislow' group 48 . To gain a consensual knowledge into the 305
MoA of HSA, common hits identified by HIP assay of these related compound were identified 306 by Venn diagram that revealed mge1/MGE1 mutant as unique common hit for the five HSA ( Fig.  307 6A). 308 309
Mge1 is a nucleotide release factor for the mitochondrial heat shock protein 70, Ssc1 that acts by 310 facilitating the release of ADP from Ssc1 49 . This process is essential for the import complex to 311 translocate nuclear-encoded proteins to their final mitochondrial destination. Both Mge1 and 312 Scc1 are components of the Tim23-Tim17 import motor complex that mediates the translocation 313 of proteins through the inner mitochondrial membrane 50 . The sensitivity of C. albicans 314 heterozygous mutants of TIM23 complex including tim23/TIM23, tim17/TIM17, tim50/TIM50, 315 ssc1/SSC1 and mge1/MGE1 was tested toward high concentration of Niclosamide (200µM). 316
While the WT parental strain had no discernable growth defect, all tested mutants were sensitive 317 when exposed to Niclosamide (Fig. 6B) . The Niclosamide-induced haploinsufficiency of the 318 TIM23 complex suggests that the C. albicans translocase machinery of the inner mitochondrial 319 membrane is required to tolerate Niclosamide and/or might be a target of this HSA. 320 321
In opposite to S. cerevisiae, MGE1 is not essential in C. albicans 51 . As for the heterozygous 322 mutant strain, the conditional homozygous mutant mge1/pTeT-MGE1 under repressive condition 323 (100µg/mL tetracycline) was also sensitive to Niclosamide (not shown). Furthermore, genetic 324 inactivation of MGE1 led to a complete filamentation defect which support the hypothesis that 325 this protein might be the target of HSA ( Fig. 6C) . 326 327
Chemical genetics of hyphal signaling using TCSA and Niclosamide as perturbers 328
The C. albicans morphogenetic switch is controlled by intertwined regulatory circuits that signal 329 different filamentation cues. The RAS/cAMP 52 , the MAPK 53 and Ume6/Hgc1 54 pathways are 330 high hierarchical regulators and signaling hubs that control the filamentation process in C. 331 albicans. To test whether Niclosamide and TCSA alter C. albicans filamentation through these 332 pathways, the effect of the two molecules was assessed in mutants overexpressing UME6, HGC1 333 and the MAPKKK, STE11 in addition to the dominant mutant Ras1 G13V . These mutants 334 constitutively formed hyphae or pseudohyphae which will determine whether antifilamentation 335 molecules act upstream or downstream these pathways. Niclosamide and TCSA blocked C. 336
albicans filamentation regardless the targeted regulators suggesting that both compounds acted 337 on effectors downstream these signaling pathways ( Fig. 7A-B Here, we uncovered that halogenated salicylanilides represent new chemical scaffolds that 361 impede specifically C. albicans virulence without affecting the commensal yeast growth. Future 362 comprehensive structure-guided medicinal chemistry investigations are required to precisely 363 point out the chemical group that lead to this discriminative antivirulence activity. Of note, the 364 non-halogenated salicylanilide scaffold (compound #3) has a strong anti-growth activity against 365
C. albicans and suggests that halogenation enhances the antivirulence activity. Halogen bonds 366 are exploited in medicinal chemistry for their steric effect to accommodate a best fitting of a 367 small molecule to occupy the binding site of its target 57 . Our data showed that chlorination was 368 more effective as compared to fluorination (compound #5 and #8) or bromination (compound 369 #11) regarding the antivirulence activity. This might be explained by the fact that, as compared 370
to the other halogens-carbon bonds, C-Cl is more stable which might allow a steady docking on 371 its virulence-related target 57 . 372 373
Regarding the mechanism of action, HSA have been associated with the perturbation of a 374 plethora of biological processes in bacteria and parasites. Salicylanilides have been shown to 375 inhibit the two-component regulatory systems, uptake of nutrients and oxidative 376 phosphorylation, and to cause leakage and membrane damage and protein aggregation 58 . 377
However, their mechanisms associated with their antifungal or antivirulence activity were not 378 investigated so far. In the current study, the transcriptional signature exhibited by C. albicans 379 cells exposed to Niclosamide suggests activation of different anaplerotic metabolic pathways that 380
can sustain the TCA cycle with metabolites such as citrate, succinate and oxaloacetate. This 381 phenomenon, so-called RTG, is most likely triggered in C. albicans cells as a consequence of the 382 dissipation of the mitochondrial potential. The HIP assays on cells treated to different HSA 383 uncovered that Mge1 might be a potential target of Niclosamide and TCSA. Indeed, genetic 384 inactivation of Mge1 led to a complete filamentation defect which supports the hypothesis that 385 this protein might be the target of HSA. 386 387
Mge1 is a nucleotide release factor that mediates the release of ADP from the heat shock protein 388 Ssc1 49 . This process is essential for the mitochondrial import complex to translocate nuclear-389 encoded proteins to mitochondria. Interestingly, this process is ΔΨm-depend which suggests that 390 the collapse of ΔΨm mediated by HSA might contribute to the malfunctioning of the 391 mitochondrial import complex and thus compromises protein translocation in the mitochondria 392 59 . Alternatively, in addition to its role as ADP-ATP recycling factor, Mge1 functions as a co-393 chaperone in the mitochondrial matrix together with Scc1 and Mdj1 to refold desaturated 394 proteins 60 . Taken together, either protein translocation or refolding functions of Mge1 could be 395 hampered by HSA which in turn lead to the filamentation defect in C. albicans. 396 397
While deep investigations are required to validate that Mge1 and/or the mitochondrial protein 398 import complex as a target of HSA, previous elegant investigations in C. albicans have shown 399 that many fungal mitochondrial proteins are therapeutic targets for antifungal development 61 . 400
Furthermore, Mge1 has been recently shown to be a key regulator of azole susceptibility 62 which 401 make the fungal mitochondria as an attractive organelle target to develop anti-virulence, anti-402 growth and anti-resistance molecules to manage fungal infection. 403 1 0
404
Methods
406
Strains and growth conditions 407
The strains used in the current study are listed and described in Table 2 . For general propagation, 408 the strains were cultured at 30°C in synthetic complete (SC; 0.67% yeast nitrogen base with 409 ammonium sulfate, 2% glucose, and 0.079% complete supplement mixture) or yeast-peptone-410 dextrose (YPD; 2% Bacto-peptone, 1% yeast extract, 2% dextrose) media supplemented with 411 uridine (50mg/L). 412
Screen of the bioactive chemical yeast library 413
To identify small molecules with antifilamentation properties, the yeast bioactive small molecule 414 library from Dr Mike Tyers (University of Montreal) consisting of 678 compounds preselected 415 from the Maybridge collection (Thermo Fisher Scientific) was screened. C. albicans SC5314 416 strain cells were grown in 96-well in SC medium supplemented with 10% FBS (Wisent) and one 417 microliter of each compound from the master library plate was dispensed into the assay plate at a 418 final concentration of 100µM. DMSO at 1% (v/v) final concentration was added as control to 419 each assay plate. After an incubation for 3h in the high-content microscope Cytation 5 (BioTek ® , 420
Thermo Fisher Scientific), images were taken in each well. Hit from this primary screen were 421 confirmed using new batch of powders ordered separately. Frequent hitters and promiscuous 422 compounds in antifungal discovery pipelines 21 were removed from our hit list. Effect of 423 antifilamentation compounds on the yeast growth of C. albicans were assessed as follow: 424 SC5314 strain was grown overnight in YPD medium at 30°C in a shaking incubator at 220 rpm. 425
Cells were then resuspended in fresh SC at an OD 600 of 0.05. A total volume of 99μl fungal cells 426 was added to each well of a flat-bottom 96-well plate in addition to 1μl of the corresponding 427 stock solution antifilamentation molecules. Plates were incubated in a Sunrise-Tecan plate reader 428 at 30°C with agitation and OD 600 readings were taken every 10min over 24h. Each experiment 429 was performed in triplicate. 430
Hyphal growth and biofilm assays 431
An overnight culture of the C. albicans strains was used to inoculate a 5mL of fresh YPD at an 432 OD 600 of 0.05. Cells were grown for 4 h at 30°C under agitation to reach the exponential phase. 433
To induce hypha, the SC5314, 6692 and 5674 strains were grown at 37°C in YPD supplemented 434 with either 10% FBS (Wisent) or 2.5mM N-acetyl-D-glucosamine ( XTT-menadione mix (0.5mg/ml XTT in PBS and 1mM menadione in acetone) was added. After 448 3 hours of incubation on dark at 37°C, 80μl of the resulting colored supernatants were used for 449 colorimetric reading at an OD 490 to assess metabolic activity of biofilms. A minimum of four 450 replicates were at least performed. Biofilm formation for C. auris was performed as for C. 451
albicans with the sole exception that cells were allowed to attach for 6 hours. 452
Transcriptional profiling 453
Overnight cultures of C. albicans strain SC5314 were diluted to an OD 600 of 0.1 in 100mL of 454 fresh YPD and grown at 30°C until an OD 600 of 0.65. The culture was divided into two volumes 455 of 50mL where 10% FBS serum was added to induce hyphae formation; one sample was 456 maintained as the control where DMSO was added, and the other treated with Niclosamide at 457 50µM. Candida cells were then incubated at 37°C and under agitation at 220 rpm for 15 min. 458
Cells were then centrifuged for 2min at 3,500 rpm, the supernatants were removed, and the 459 samples were quick-frozen and stored at 80°C. 460
RNA extractions, cDNA labelling and microarrays procedures were performed as described by 461
Chaillot et al. 65 allele and the control strain DH545 were allowed to filament in Spider medium at 30°C in the 499 presence of HSA for 2h. 500
Measurements of mitochondrial membrane potential 501
The mitochondrial membrane potential of C. albicans cells was measured using both fluorescent 502 probes, JC-1 and MitoTracker Red CMXRos (ThermoFisher). Exponentially grown C. albicans 503 cells were washed twice with PBS and treated or not with different concentrations of either 504
Niclosamide or TCSA for 30 min under hyphae promoting conditions. JC1 and MitoTracker 505
were added to C. albicans cells at final concentration of 5 µM and 100 nM, respectively, and 506 cells were incubated at 30°C for 30 min in dark. Cells were then washed twice with PBS to 507 remove residual dyes. Fore JC-1, fluorescence was quantitatively assessed using flow cytometry 508 (BD FACSCanto™) using 10 6 C. albicans cells. For the MitoTracker assay, the fluorescence was 509 measured using the Cytation 5 plate reader (BioTek ® ). Results of JC-1 and MitoTracker assays 510
were measured as the mean of fluorescence intensities of at least three independent experiments. 511
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We are grateful to Mike Tyers and Susan Moore (Université de Montreal) for providing the yeast 513 bioactive small molecule library. We thank Martine Raymond ( albicans SC5314 strain was assessed using LDH release assay. Cell damage was calculated as 788 percentage of LDH activity of HSA-treated experiment relatively to that of the control 789 experiment (C. albicans invading HT-29 cells in the absence of HSA). Results are represented as 790 the mean of three independent replicates. 791 Carbohydrate metabolic process GAL1, GAL10, TPS2, ICL1, PFK26, MLS1, PFK27, HSP21, GPD1, PYC2, XKS1, NTH1, GSY1, HSP104 6.25e-02
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Down-regulated transcripts
Lipid biosynthetic process CWH8, FEN1, LCB2, DGK1, AYR1, ERG6, LAC1, IDI1, PEL1, CYB5, EPT1, COQ1, ERG25, CHO2, NDT80 1.34e-03
Regulation of protein serine/threonine kinase activity RHO2, SOL1, WSC1, PBS2, CLN3, CIP1, CLG1 7.82e-03
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